Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shanu Modi

Showing results (81-90 of 115) with videos related to

Pageof 12
Sort By:
Cancer Discovery|November 10, 2025
Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and BindingWanyi Chen, Avantika Gupta, Nicholas Mai, et al.
NPJ Breast Cancer|April 20, 2022
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastasesDavid B Page, Kathryn Beal, Stefanie N Linch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerChau Dang, Neil Iyengar, Farrah Datko, et al.
JACC. Cardiooncology|June 19, 2025
Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted TherapyAnthony F Yu, Chau T Dang, Chaya S Moskowitz, et al.
Breast Cancer (Tokyo, Japan)|June 17, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 studyToshinari Yamashita, Joo Hyuk Sohn, Eriko Tokunaga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guidelineNaren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, et al.
Cancer Discovery|October 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup AnalysisGuy Jerusalem, Yeon Hee Park, Toshinari Yamashita, et al.
The Oncologist|May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBCNaoto T Ueno, Francesco Cottone, Kyle Dunton, et al.
JAMA Network Open|November 28, 2019
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical TrialNeil M Iyengar, Lillian M Smyth, Diana Lake, et al.
Clinical Breast Cancer|February 12, 2014
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancerKomal Jhaveri, Sarat Chandarlapaty, Diana Lake, et al.
Pageof 12

Showing results (81-90 of 115) with videos related to

Sort By:
Pageof 12
Cancer Discovery|November 10, 2025
Trastuzumab Deruxtecan (T-DXd) Resistance via Loss of HER2 Expression and BindingWanyi Chen, Avantika Gupta, Nicholas Mai, et al.
NPJ Breast Cancer|April 20, 2022
Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/- trastuzumab in patients with breast cancer brain metastasesDavid B Page, Kathryn Beal, Stefanie N Linch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2014
Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancerChau Dang, Neil Iyengar, Farrah Datko, et al.
JACC. Cardiooncology|June 19, 2025
Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted TherapyAnthony F Yu, Chau T Dang, Chaya S Moskowitz, et al.
Breast Cancer (Tokyo, Japan)|June 17, 2024
Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer: subgroup analysis of the DESTINY-Breast04 studyToshinari Yamashita, Joo Hyuk Sohn, Eriko Tokunaga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guidelineNaren Ramakrishna, Sarah Temin, Sarat Chandarlapaty, et al.
Cancer Discovery|October 18, 2022
Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup AnalysisGuy Jerusalem, Yeon Hee Park, Toshinari Yamashita, et al.
The Oncologist|May 11, 2025
Patient-reported outcomes from DESTINY-Breast04: trastuzumab deruxtecan versus physician's choice of chemotherapy in patients with HER2-low mBCNaoto T Ueno, Francesco Cottone, Kyle Dunton, et al.
JAMA Network Open|November 28, 2019
Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Phase 2 Clinical TrialNeil M Iyengar, Lillian M Smyth, Diana Lake, et al.
Clinical Breast Cancer|February 12, 2014
A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancerKomal Jhaveri, Sarat Chandarlapaty, Diana Lake, et al.
Pageof 12